Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 340

1.
4.

Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line.

Webber MM, Bello D, Kleinman HK, Wartinger DD, Williams DE, Rhim JS.

Carcinogenesis. 1996 Aug;17(8):1641-6.

5.

Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18.

Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS.

Carcinogenesis. 1997 Jun;18(6):1215-23.

6.
7.

Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression.

Webber MM, Quader ST, Kleinman HK, Bello-DeOcampo D, Storto PD, Bice G, DeMendonca-Calaca W, Williams DE.

Prostate. 2001 Apr;47(1):1-13.

PMID:
11304724
8.

Phenotypic characterization of immortalized normal and primary tumor-derived human prostate epithelial cell cultures.

Schwab TS, Stewart T, Lehr J, Pienta KJ, Rhim JS, Macoska JA.

Prostate. 2000 Jul 1;44(2):164-71.

PMID:
10881026
9.

Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells.

Webber MM, Bello D, Kleinman HK, Hoffman MP.

Carcinogenesis. 1997 Jun;18(6):1225-31.

10.

Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression.

Wu GJ, Wu MW, Wang SW, Liu Z, Qu P, Peng Q, Yang H, Varma VA, Sun QC, Petros JA, Lim SD, Amin MB.

Gene. 2001 Nov 14;279(1):17-31.

PMID:
11722842
11.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
12.

Reversion of human prostate tumorigenic growth by azatyrosine.

Benoit RM, Eiseman J, Jacobs SC, Kyprianou N.

Urology. 1995 Sep;46(3):370-7.

PMID:
7660512
13.

Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model.

Quader ST, Bello-DeOcampo D, Williams DE, Kleinman HK, Webber MM.

Mutat Res. 2001 Sep 20;496(1-2):153-61.

PMID:
11551491
14.

A novel neoplastic primary tumor-derived human prostate epithelial cell line.

Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, Sesterhenn IA, McLeod DG, Arnstein P, Taylor DO, Hukku B, Rhim JS.

Int J Oncol. 2003 Jun;22(6):1311-7.

PMID:
12738999
15.
16.

N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention.

Sharp RM, Bello-DeOcampo D, Quader ST, Webber MM.

Mutat Res. 2001 Sep 20;496(1-2):163-70.

PMID:
11551492
17.

Phenotypic and genotypic characterization of commonly used human prostatic cell lines.

Mitchell S, Abel P, Ware M, Stamp G, Lalani E.

BJU Int. 2000 May;85(7):932-44.

18.

Malignant transformation in a nontumorigenic human prostatic epithelial cell line.

Hayward SW, Wang Y, Cao M, Hom YK, Zhang B, Grossfeld GD, Sudilovsky D, Cunha GR.

Cancer Res. 2001 Nov 15;61(22):8135-42.

19.

LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW.

Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2).

PMID:
10881018
20.

Human prostate carcinogenesis.

Rhim JS, Kung HF.

Crit Rev Oncog. 1997;8(4):305-28. Review.

PMID:
9622052
Items per page

Supplemental Content

Write to the Help Desk